12.58
price up icon0.72%   0.09
after-market Dopo l'orario di chiusura: 12.58
loading
Precedente Chiudi:
$12.49
Aprire:
$12.1
Volume 24 ore:
1.78M
Relative Volume:
1.17
Capitalizzazione di mercato:
$1.26B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-26.77
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-2.40%
1M Prestazione:
+20.04%
6M Prestazione:
-13.24%
1 anno Prestazione:
+23.09%
Intervallo 1D:
Value
$11.85
$12.77
Intervallo di 1 settimana:
Value
$11.85
$13.22
Portata 52W:
Value
$7.55
$18.51

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
Nome
Ars Pharmaceuticals Inc
Name
Telefono
858-771-9307
Name
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
SPRY's Discussions on Twitter

Confronta SPRY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
12.58 1.26B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-07 Iniziato Scotiabank Sector Outperform
2025-02-10 Iniziato Oppenheimer Outperform
2024-08-20 Iniziato Cantor Fitzgerald Overweight
2024-08-13 Aggiornamento Raymond James Outperform → Strong Buy
2024-08-12 Reiterato Leerink Partners Outperform
2024-07-25 Iniziato Raymond James Outperform
2024-03-05 Aggiornamento Leerink Partners Market Perform → Outperform
2024-02-20 Aggiornamento William Blair Mkt Perform → Outperform
2023-09-20 Downgrade William Blair Outperform → Mkt Perform
2023-01-31 Iniziato Wedbush Outperform
2023-01-03 Iniziato William Blair Outperform
2022-12-13 Iniziato SVB Leerink Outperform
Mostra tutto

Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie

pulisher
Mar 26, 2025

Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st

Mar 26, 2025
pulisher
Mar 26, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance

Mar 26, 2025
pulisher
Mar 25, 2025

Long Term Trading Analysis for (SPRY) - Stock Traders Daily

Mar 25, 2025
pulisher
Mar 24, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor

Mar 24, 2025
pulisher
Mar 22, 2025

ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

neffy From ARS Pharmaceuticals, Inc - Pharmacy Times

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

Raymond James maintains $28 target on ARS Pharma stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Sector Update: Health Care - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings -March 20, 2025 at 07:45 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M -March 20, 2025 at 07:13 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 EPS $0.48, vs. FactSet Est of $-0.04 Loss - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

ARS Pharma Crushes Q4 with $49.9M Profit as Neffy Launch Gains Momentum - StockTitan

Mar 20, 2025
pulisher
Mar 18, 2025

This company’s epinephrine nasal spray reverses allergic reactions—no needle required - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company

Mar 18, 2025
pulisher
Mar 14, 2025

(SPRY) Investment Report - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 09, 2025

Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025
pulisher
Mar 08, 2025

Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Ars pharmaceuticals director Laura Shawver sells $560,445 in stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients - Reuters

Mar 07, 2025
pulisher
Mar 07, 2025

San Diego biotech gets FDA approval for EpiPen alternative for kids - MSN

Mar 07, 2025
pulisher
Mar 07, 2025

Exploring High Growth Tech Stocks in the US Market - Simply Wall St

Mar 07, 2025
pulisher
Mar 07, 2025

California biotech company gets FDA approval for EpiPen alternative for kids - East Bay Times

Mar 07, 2025
pulisher
Mar 07, 2025

Scotiabank sets $30 target for ARS Pharmaceuticals stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Scotiabank sets $30 target for ARS Pharmaceuticals stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients - Pharmaceutical Executive

Mar 06, 2025
pulisher
Mar 06, 2025

FDA Approves Low-Dose Neffy Epinephrine Spray for Young Kids - Allergic Living

Mar 06, 2025

Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):